Discussion Topic: Time to Benefit and Harm of Direct Oral Anticoagulants in Device-Detected Atrial Fibrillation: A Pooled Analysis of the NOAH-AFNET 6 and ARTESiA Trials
William H. Sauer, MD, FHRS, CCDS, Brigham and Women’s Hospital is joined by Rod S. Passman, MD, FHRS, Northwestern University and Graham Peigh, MD, MS, Northwestern Memorial Hospital to discuss the direct oral anticoagulants (DOACs) reduce stroke risk in patients with device-detected atrial fibrillation (DD-AFib) but increase major bleeding risk. The time to benefit (TTB) and time to harm (TTH) are not well quantified.
Host: William H. Sauer, MD, FHRS, CCDS
Guests: Rod S. Passman, MD, FHRS and Graham Peigh, MD, MS
Speaker and Article Information: Download
Topic
- The Lead
Resource Type
- Podcasts
Related Resources

Podcasts
The Lead Episode 112: A Discussion of Brugada Syndrome Ablation for the Prevention of VS Episodes (BRAVE) LIVE from Heart Rhythm 2025 in San Diego
July 17, 2025

Podcasts
The Lead Episode 111: A Discussion of Computed Tomography-Guided Catheter Ablation for Ventricular Tachycardia LIVE at HRS 2025 in San Diego
July 9, 2025

Podcasts
The Lead Episode 110: A Discussion of Left Bundle area Pacing in Hypertrophied Hearts...LIVE from HRS 2025 in San Diego
July 3, 2025